Cancer‐associated fibroblast expression of glutamine fructose‐6‐phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer

• Published in: The journal of pathology. Clinical research Vol. 9; no. 5; pp. 391 - 408
• Main Authors: Yang, Shuo, Li, Guoli, Yin, Xin, Wang, Yufei, Jiang, Xinju, Bian, Xiulan, Fang, Tianyi, Yin, Shengjie, Zhang, Lei, Xue, Yingwei
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.09.2023; Wiley
• Subjects: Algorithms; Biotechnology; Cancer therapies; Cancer-Associated Fibroblasts - pathology; cancer‐associated fibroblasts; Cell Line, Tumor; Cells; Chemotherapy; Cisplatin; Cytokines; DNA microarrays; Extracellular matrix; Fibroblasts; Fructose-6-phosphate; Gastric cancer; Gastrointestinal surgery; Gene expression; Genes; Genomes; Genomics; GFPT2; Glucose; Glutamine; Glutamine - metabolism; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - genetics; Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) - metabolism; Guanylate cyclase; Humans; immune microenvironment; Immunohistochemistry; Infiltration; Lymph nodes; Metabolism; Metastases; Metastasis; Microenvironments; Original; Paclitaxel; Patients; Prognosis; Protein arrays; Proteins; RNA, Messenger - metabolism; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Stromal cells; Transcriptomes; Tumor Microenvironment; Western blotting; China; cancer-associated fibroblasts; immune microenvironment; gastric cancer; prognosis; GFPT2
• ISSN: 2056-4538; 2056-4538
• DOI: 10.1002/cjp2.333

Glutamine fructose‐6‐phosphate aminotransferase 2 (GFPT2) is a rate‐limiting enzyme in hexosamine biosynthesis involved in the occurrence and progress of many cancers. What role it plays in gastric cancer (GC) is still unclear. In this study, transcriptome sequencing data from the Harbin Medical University (HMU)‐GC cohort and The Cancer Genome Atlas (TCGA) dataset were combined with the HMU‐TCGA training cohort to analyze the biological function and clinical significance of GFPT2. The correlation of GFPT2 with immune cells and stromal cells was analyzed in the GC immune microenvironment through transcriptome sequencing data and a public single‐cell sequencing database. In cell lines, GC tissues, and the tissue microarray, GFPT2 protein expression was confirmed by western blotting and immunohistochemistry. The mRNA of GFPT2 was highly expressed in the tumor (p < 0.001), and GC cells and tumors expressed high levels of GFPT2 protein. Compared to low expression, high GFPT2 mRNA expression was associated with higher levels of tumor invasion, higher pathological stages, and poor prognosis (p = 0.02) in GC patients. In a drug susceptibility analysis, GFPT2 mRNA expression was associated with multiple chemotherapeutic drug sensitivity, including docetaxel, paclitaxel, and cisplatin. Gene enrichment analysis found that GFPT2 was mainly primarily involved in the extracellular matrix receptor interaction pathway. The ESTIMATE, CIBERSORT, and ssGSEA algorithms showed that GFPT2 was associated with immune cell infiltration. In addition, GFPT2 was more likely to be expressed within cancer‐associated fibroblasts (CAFs), and high levels of GFPT2 expression were highly correlated with four CAFs scores (all p < 0.05). Finally, a prognostic model to assess the risk of death in GC patients was constructed based on GFPT2 protein expression and lymph node metastasis rate. In conclusion, GFPT2 plays an essential role in the function of CAFs in GC. It can be used as a biomarker to assess GC prognosis and immune infiltration.